| Name | Title | Contact Details |
|---|
iwis is one of the worlds leading suppliers of chain system solutions for the automotive industry as well as for drive and conveyor purposes in numerous industries. What began with a bicycle chain quickly grew into a successful, likeable family business - and ultimately into a global technology leader in the field of high-quality chain system solutions and engineering service provider. By expanding our product range with high-precision stamped and bent parts as well as precision plastic parts, multi-component and composite parts, we continue to lead the automotive sector towards the future in terms of mobility and regenerative energy generation. Our product brands JWIS, ELITE,FLEXON as well as EUROCHAIN, ECOPLUS and MEGALIFE offer suitable solutions for every quality requirement. Our team counts more than 3,000 employees working at numerous international locations: dedicated professionals working in the 3 divisions Mobility Systems, Drive Systems, and Mechatronics on development and optimization as well as in manufacturing and quality testing. For solutions that really move the world. Our goal is perfection - no more, no less. The expertise of our engineers lies in identifying trends, developing new material and manufacturing technologies, and customized solutions. Our research and development competence center stands for innovation and partnership. This makes us a strong and reliable partner. Imprint: https://www.iwis.com/en-gb/imprint
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
IHP offers health plan options to companies across the country, with the goal of providing affordable healthcare with a clear, and distinct, schedule of benefits. Our plans are guaranteed issue, zero deductible, and co-pay driven—well change the way you think about healthcare.